United Therapeutics Corp (NASDAQ:UTHR) recently saw activity involving its Chief Financial Officer and Treasurer, James Edgemond. On June 1, 2026, Mr. Edgemond sold a total of 10,000 shares of the company's common stock. The aggregate value realized from these sales was approximately $5,478,663. The selling prices were observed across a range, specifically between $544.67 and $554.94 per share. This transaction followed a period where UTHR had demonstrated strong performance, achieving a 67% return over the previous year and trading near its 52-week high valuation of $609.35.
It is important to note that these sales were not discretionary. They were executed as part of a pre-arranged Rule 10b5-1 trading plan, which Mr. Edgemond had originally established on October 31, 2025. Each sale transaction involved multiple individual trades, and the reported prices are reflective of weighted averages within their respective price ranges.
Concurrently with the sales activity, Mr. Edgemond also increased his holdings. On that same date, he acquired another 10,000 shares of United Therapeutics common stock by exercising vested options. These options were exercised at a cost of $117.76 per share, resulting in a total acquisition value of $1,177,600. This purchase was also conducted under the stated Rule 10b5-1 trading plan.
Beyond the executive transactions, the company's underlying financial and operational data present a mixed picture. Financially, United Therapeutics reported first-quarter revenue of $781.5 million. This figure missed the consensus estimate provided by analysts, which was set at $797.4 million. Similarly, revenues specifically attributed to Tyvaso were $457.5 million, falling short of the expected $478.6 million. Furthermore, net income was reported at $274.9 million, which was also below the anticipated level of $320.5 million.
Despite the quarterly revenue shortfall, UTHR maintains several strong operational fundamentals. The company reports an impressive gross profit margin of 87% and stands at earnings per share (EPS) of $27.07. From a valuation perspective, InvestingPro analysis suggests that the stock is currently trading slightly above its calculated Fair Value.
In terms of corporate development, United Therapeutics made significant announcements regarding its drug pipeline. The company's TETON-1 phase 3 study for nebulized Tyvaso in idiopathic pulmonary fibrosis achieved its primary endpoint. These findings were published in the New England Journal of Medicine and highlighted that Tyvaso demonstrated effectiveness by reducing the risk of clinical worsening events, underscoring its potential use.
The company also secured a notable collaboration with Varda Space Industries. This partnership aims to explore microgravity-based pharmaceutical processing for developing treatments designed for rare pulmonary diseases. The plan involves utilizing Varda's orbital manufacturing and reentry platform to enhance the properties of therapeutic compounds, suggesting an advanced approach to drug development.
Market sentiment has been mixed following these developments. On the analyst front, TD Cowen reiterated a 'Buy' rating on United Therapeutics, maintaining its price target at $675.00. However, BTIG issued a contrasting report, reiterating a 'Neutral' rating following the company’s first-quarter earnings miss.
Following these transactions and announcements, Mr. Edgemond directly holds 18,876 shares of United Therapeutics common stock.